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Abstract
Background: Pancreatic cancer (PaC) remains extremely lethal worldwide even after resection. PaC resection rates
are low, making prognostic studies in resected PaC difficult. This large international population-based study aimed
at exploring factors associated with survival in patients with resected TNM stage I–II PaC receiving chemotherapy
and at developing and internationally validating a survival-predicting model.
Methods: Data of stage I–II PaC patients resected and receiving chemotherapy in 2003–2014 were obtained from
the national cancer registries of Belgium, the Netherlands, Slovenia, and Norway, and the US Surveillance, Epidemiology,
and End Results (SEER)-18 Program. Multivariable Cox proportional hazards models were constructed to investigate the
associations of patient and tumor characteristics with overall survival, and analysis was performed in each country
respectively without pooling. Prognostic factors remaining after backward selection in SEER-18 were used to build a
nomogram, which was subjected to bootstrap internal validation and external validation using the European datasets.
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Results: A total of 11,837 resected PaC patients were analyzed, with median survival time of 18–23months and 3-year
survival rates of 21–31%. In the main analysis, patient age, tumor T stage, N stage, and differentiation were associated
with survival across most countries, with country-specific association patterns and strengths. However, tumor location was
mostly not significantly associated with survival. Resection margin, hospital type, tumor size, positive and harvested lymph
node number, lymph node ratio, and comorbidity number were associated with survival in certain countries where the
information was available. A median survival time- and 1-, 2-, 3-, and 5-year survival probability-predictive nomogram
incorporating the backward-selected variables in the main analysis was established. It fits each European national cohort
similarly well. Calibration curves showed very good agreement between nomogram-prediction and actual observation.
The concordance index of the nomogram (0.60) was significantly higher than that of the T and N stage-based model (0.
56) for predicting survival.
Conclusions: In these large international population-based cohorts, patients with resected PaC receiving chemotherapy
have distinct characteristics independently associated with survival, with country-specific patterns and strengths. A robust
benchmark population-based survival-predicting model is established and internationally validated. Like previous models
predicting survival in resected PaC, our nomogram performs modestly.
Keywords: Pancreatic cancer, Resection, Chemotherapy, Survival, Prognostic factors, Benchmark population-based
nomogram, International real-world cohort study,
Background
Worldwide, pancreatic cancer (PaC) is the seventh leading
cause of cancer-related mortality [1]. Resection remains the
cornerstone of curative treatment for medically fit patients
with resectable locoregional PaC [2]. However, only a small
proportion of patients with PaC undergo resection. In the
United States (US) and Europe during 2012–2014, resec-
tion rates ranged from 13% (Estonia) to 21% (Slovenia) for
all-stage PaC and from 35% (Norway) to 69% (Denmark)
for stage I–II PaC [3]. The 3-year overall survival remains
poor even for patients with stages I–II PaC who underwent
resection (< 60 years, 23–39%; 60–69 years, 16–31%; and ≥
70 years, 17–30%) [4]. Chemotherapy has been routinely
recommended for resected PaC [5–7]; however, it remains
challenging to get many patients to adjuvant therapy after
pancreatectomy [8].
Various prognostic factors for PaC including clinical/
pathological (e.g., tumor stage, size, differentiation, lymph
node status, resection margin, and peri-neural and blood
vessel invasion [9–15]), genetic (e.g., KRAS, TP53, SMAD4,
and some DNA damage repair genes (e.g., BRCA1/2 and
MLH1) [16–18]), and immunological variables (e.g., CD3,
CD8, CD68, PD-L1, and HHLA2 [19–21]) have been re-
ported. Further large international comparative studies on
survival-associated factors at the population level could
help to identify differences across countries.
Patients with resected PaC who undergo chemotherapy
are a selected group of all PaC patients and have distinct
characteristics [8]. Even within this patient group, survival is
heterogeneous. A prognostic model for this specific patient
population is important and desirable and could facilitate
clinical counseling by informing both patients and doctors
of predicted individualized patient survival, guide plans on
follow-up and surveillance, aid to survival stratification in
international studies, and offer the baseline survival esti-
mates for further molecular or genetic investigations. Fur-
thermore, for resected patients considering subsequent
chemotherapy, the predicted results could potentially en-
courage a proportion of patients with specific characteristics
to further receive the standard postsurgical care. Stage is
the major prognostic factor for PaC. Notably, survival of pa-
tients with disease of the same TNM stage might vary
greatly [14]. Other prognostic factors such as patient age
and tumor differentiation could improve individualized
survival-prediction. A model incorporating all these factors
can be intuitively illustrated using a nomogram [22]. Apart
from two institutional nomograms predicting postsurgical
survival in overall patients [23, 24], population-based
survival-predicting models specifically for resected PaC pa-
tients receiving chemotherapy with international validations
and robustness have not been found.
To our knowledge, we herein report the first large
international population-based investigation into factors
associated with survival in patients with resected TNM
stage I–II PaC receiving chemotherapy. We further con-
struct a population-based survival-predicting model with
international validations.
Methods
Patients
Population-based data of resected PaC patients were ob-
tained from the national cancer registries of Belgium,
the Netherlands, Slovenia, and Norway, and the US Sur-
veillance, Epidemiology, and End Results (SEER)-18 [25]
database. Data quality was previously described [3].
Institution-based data were not included due to the
highly selected patients. An extensive attempt was made
to contact population-based cancer registries, and the
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contacted registries together with reasons for exclusion
are shown in Additional file 1: Table S1. The participat-
ing European national registries, located in Western,
Southern, and Northern Europe were those able to pro-
vide quality data according to a standardized uniformed
data-request form, which ensured the robustness of the
results. All variables were uniformly (re)coded across regis-
tries. While there were other national population-based
registries, they were not always able to provide eligible
treatment, TNM staging, or survival data. All patient-level
data were anonymous. This real-world observational study
was approved by the Ethics Committee of Medical Faculty
Heidelberg.
Patients with diagnosis based on death certificate only
(DCO)/autopsy or with unknown/obscure follow-up time
or vital status were excluded (Additional file 1: Table S2).
Only patients with microscopically confirmed diagnoses
of primary invasive TNM stage I–II adenocarcinomas of
the exocrine pancreas who underwent surgical resection
in 2003 until 2014 were selected. The time period was se-
lected based on data availability and the fact that the fifth
and prior editions of TNM staging were incompatible with
the sixth/seventh versions used during 2003–2017 [7].
Since chemotherapy is standard for patients with resected
PaC [5–7], we only included those receiving chemother-
apy. Individuals with benign/premalignant tumors,
non-PaC neoplasms involving the pancreas, neuroendo-
crine tumors/carcinoids, cystic/mucinous/serous tumors,
acinar cell tumors, stromal tumors, sarcomas, germ-cell
neoplasms, lymphomas, or peri-ampullar tumors were
also excluded (Additional file 1: Table S3). To minimize
the effect of the potential heterogeneity in surgery quality
and perioperative care, we excluded cases surviving < 3
months. Patients with stage III or IV PaC were also ex-
cluded since resection is not routinely recommended for
these patients [5–7].
Information on demographic (sex and age), clinical
(year of diagnosis/surgery and treatment), and patho-
logic characteristics (topology, morphology, and TNM
stage) was retrieved from all participating countries.
Data on resection margin (the Netherlands and
Slovenia), hospital type (Belgium and the Netherlands),
Eastern Cooperative Oncology Group (ECOG) perform-
ance status score (Belgium), comorbidities (Eindhoven,
the Netherlands), resection type (the US and the
Netherlands), tumor size (the US), and positive and har-
vested lymph node numbers (the US and the
Netherlands) were only available in certain registries.
Resection was defined as surgical removal of primary
tumor, regardless of being curative or palliative and ex-
tents of excision and lymphadenectomy. Tumor topog-
raphy and morphology were based on the International
Classification of Diseases for Oncology (third edition).
Stage was defined following the TNM staging system
(sixth/seventh edition) and was a combination of patho-
logic and clinical stages with priority given to pathologic
staging. Lymph node ratio was calculated by dividing the
number of positive lymph nodes by the number of
harvested lymph nodes. Vital status was based on valid
national mortality registrations and official population
registers.
Statistical analyses
Data in each country were analyzed separately without
pooling, considering the potential heterogeneity across
countries and to avoid the impact of any single large co-
hort. Descriptive results were reported as the smallest to
the largest proportions for categorical variables or me-
dians/means for continuous variables across countries.
The cancer incidence rates by sex in each country were
retrieved from the Cancer Incidence in Five Continents
Volume XI (CI5 XI) by the International Agency for Re-
search on Cancer (IARC), World Health Organization
(WHO) (http://ci5.iarc.fr/CI5-XI/Default.aspx), which
reports the incidence of cancers diagnosed from 2008 to
2012, standardized to the World (WHO 2000–2025)
Standard Population.
The Kaplan-Meier method was applied to calculate
survival time and rates. Since patients surviving < 3
months were excluded in this study, the 6- and 9-month
survival was calculated as the short-term outcome. The
1-, 2-, 3-, and 5-year survival was computed as the
long-term outcome. To assess the independent impact
of potential prognostic factors on survival, Cox propor-
tional hazards regression was used. Variables including
year of diagnosis, age, sex, tumor location, T and N
stages, and differentiation were included as covariates in
the main multivariable models. For complete-case ana-
lysis, patients with missing data were excluded in multi-
variable analyses. In the US, results for the white
patients were computed for comparison with the total
patients, for whom main analyses were performed. In
registries with available information, resection margin,
hospital type, tumor size, positive and harvested lymph
node numbers, lymph node ratio, T and N stages accord-
ing to the eighth edition following Kamarajah et al. [26],
ECOG score, resection type, and comorbidities were in-
corporated one by one into the main models to examine
the survival association for each of them. The propor-
tional hazards assumption was verified for all variables
by plotting the logarithm of the negative logarithm of
the survival function against the logarithm of survival
time [27].
Data were centrally analyzed in the German Cancer
Research Center. Results were considered statistically
significant at two-sided P < 0.05. Analyses were con-
ducted using the SAS software (version 9.4, SAS
Institute Inc.).
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Nomogram construction and validation
The SEER-18 dataset, the largest of the included data-
sets, was used as the training set for nomogram con-
struction (models based on the other cohorts did not
reveal markedly better performance). Age, sex, tumor lo-
cation, T and N stages, and differentiation were entered
as potentially relevant prognostic factors into the initial
full multivariable Cox proportional hazards regression
model, and the final model was selected through a back-
ward step-down process using the likelihood ratio test
with the Akaike information criterion as a stopping rule
[28]. To permit nonlinear associations, continuous vari-
ables were modeled using restricted cubic splines where
appropriate [28]. Points assigned to each variable in-
cluded in the nomogram to predict the median survival
time and 1-, 2-, 3-, and 5-year survival probability were
proportional to the effect size of that variable in the final
multivariable model. To facilitate clinical use, a corre-
sponding online prognostic tool was created with Evi-
dencio (https://www.evidencio.com/).
The nomogram was subjected to 1000 bootstrap
resamples for internal validation of the training US co-
hort and was externally validated using the European
datasets to assess the international generalizability of the
model. The model performance and discrimination abil-
ity for predicting survival was numerically evaluated by
computing Harrell’s concordance index (C-index) [28].
Comparison of C-indexes of different models followed
Hanley et al. [29]. Calibration of the nomogram for 1-,
2-, 3-, and 5-year survival was done by comparing the
predicted with the observed survival. Bootstrapping was
used for bias correction [28].
In sensitivity analyses for the training US cohort,
C-indexes were re-calculated after replacing continuous
age with age group, N stage with positive lymph node
number or lymph node ratio, and sixth/seventh edition
of cancer stages with the eighth version, after adding
harvested lymph node number and/or tumor size, after
limiting patients to those diagnosed after 2009 or white
patients, and after stratifying patients by tumor location.
The survival and rms packages in R 3.4.1 (http://www.r-
project.org) were used.
Results
Patient characteristics
In total, 168,949 PaC patients were registered in the
population-based registries in 2003/2004–2013/2014
with follow-up until 2015–2016. After excluding patients
diagnosed based on DCO/autopsy (n = 4403), unresected
(n = 137,605), receiving no/unknown chemotherapy
(n = 11,465), with microscopically unconfirmed tumors
or with tumors of ineligible pathology (n = 1418), with
stage 0/III/IV/unknown tumors (n = 1856), and with sur-
vival< 3months or unknown (n = 365), 11,837 patients
were eligible for analysis (Additional file 1: Table S2).
The detailed counts and frequencies for discrete vari-
ables and medians and interquartile ranges for continu-
ous variables are shown in Table 1. Age-standardized
PaC incidence was higher for males than for females.
Among the participating countries, incidence for males
was lowest in Belgium and the Netherlands (7.4 per
100,000) and highest in Slovenia (9.3 per 100,000); for
females, incidence was lowest in Belgium (5.6 per
100,000) and highest in the US, Slovenia, and Norway
(6.5 per 100,000).
Of the analyzed patients, 52–76% were diagnosed in 2010
or later. The proportion of women ranged from 42%
(Slovenia) to 51% (Norway) across countries. While the pro-
portion of women was almost identical to that of men in the
US, the Netherlands, and Norway, there was a smaller pro-
portion of women in Slovenia (42%). The median age ranged
from 61 (Slovenia) to 65 years (the US and Belgium) across
countries. Most patients were ≥ 60 years (58% (Slovenia) to
71% (Norway)). The proportion of patients aged ≥ 70 years
was greatest in the US (34%) and smallest in Slovenia (19%).
Only 4% (Norway) to 9% (the Netherlands and Slovenia) of
patients were < 50 years old. Tumors were most commonly
located at pancreas head (82% (Belgium) to 92% (Slovenia)).
Only 3% (the Netherlands) to 7% of cancers (the US and
Belgium) were located at pancreas body and 3% (Slovenia)
to 11% (Belgium) at pancreas tail. Only a minority of pa-
tients had T1 (0% (Slovenia) to 8% (Norway)) or T2 cancers
(7% (Slovenia) to 26% (Norway)). N1 tumors comprised
55% (Norway) to 84% of all cancers (Slovenia). Most patients
had either moderately differentiated (40% (Slovenia) to 63%
(Norway)) or poorly differentiated/undifferentiated tumors
(33% (Belgium) to 50% (Slovenia)). Only 3% (Norway) to
15% of cancers (Belgium) were well-differentiated.
Survival outcomes
The median survival time ranged from 18 (Slovenia) to
23months (the US) across countries (Fig. 1). The short-
and long-term survival outcomes are shown in Table 2.
The 6-month survival rate ranged from 94% (the US) to
97% (the Netherlands), and the 9-month survival rate
varied from 79% (Slovenia) to 90% (Norway). Regarding
longer term outcomes, the 1-year survival rate ranged
from 69% (Slovenia) to 79% (the Netherlands), and the
3-year survival rate ranged from 21% (Slovenia) to 31%
(the US). The 5-year survival rate was lowest in Slovenia
(10%), which was about half of that in the US (19%), the
Netherlands (20%), or Norway (21%).
Survival-associated factors
Results from multivariable Cox regression are shown in
Table 3, and only significant results are described. In-
creasing age was associated with worse survival in the
US (HR per year = 1.01), Belgium (HR = 1.02), and
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Norway (HR = 1.04). Survival was significantly worse in
men only in the US (HR = 1.10) and in pancreas body
compared to head tumors in Norway (HR = 2.67). Com-
pared to T3 cancers, T1 cancers were associated with
higher survival in all investigated countries (HR = 0.17–
0.70), while T2 cancers were associated with better sur-
vival only in the US (HR = 0.86). Negative nodal status
was associated with significantly higher survival in the US
(HR = 0.65), Belgium (HR = 0.78), and the Netherlands
(HR = 0.51). Better differentiation was significantly associ-
ated with higher survival in all countries except Slovenia
and Norway, and the HRs for well- and intermediately
versus poorly/undifferentiated tumors were 0.48–0.68 and
0.61–0.81, respectively. Association patterns and strengths
were similar between white and overall US patients.
Associations with further variables were explored in coun-
tries with available relevant information (Table 4). In the
Netherlands, positive resection margin was associated with
worse survival in (HR = 1.36), and resection in academic
hospital was associated with better survival (HR = 0.79). In
the US, larger tumor size was associated with inferior sur-
vival, and replacing T stage according to the sixth/seventh
edition with the eighth edition revealed similar association
patterns and strengths. In the US and the Netherlands, while
increasing metastatic node number (HR per positive lymph
node = 1.05 and 1.07) and lymph node ratio (HR= 2.60 and
3.15) were associated with inferior survival, more harvested
nodes suggested better survival (both HR per harvested
node = 0.99). Following the eighth version of TNM staging,
N1 (HR = 1.42 and 1.68) and N2 stages (HR= 1.84 and 2.43)
were associated with worse survival compared to N0 stage
in the US and the Netherlands. In Eindhoven, the
Netherlands, more comorbidities were associated with infer-
ior survival (e.g., HR≥ 2 vs. 0 comorbidities = 1.86).
Table 1 Demographic and clinical characteristics of resected pancreatic cancer patients1
Variable Category The US Belgium The Netherlands Slovenia Norway
Incidence (per 100,000)2 Male 8.6 7.4 7.4 9.3 7.8
Female 6.5 5.6 6.1 6.5 6.5
Years of diagnosis 2004–2015 2004–2013 2003–2014 2003–2013 2003–2014
n 9519 1105 982 118 113
Diagnosis in 2010 or later Yes 5635 (59) 579 (52) 747 (76) 67 (57) 79 (70)
Sex Female 4671 (49) 522 (47) 483 (49) 50 (42) 58 (51)
Age (years) Median (interquartile range) 65 (58–72) 65 (58–71) 64 (57–69) 61 (54–68) 63 (59–70)
Mean ± standard deviation 65 ± 10 64 ± 10 62 ± 9 61 ± 9 64 ± 8
< 50 706 (7) 90 (8) 92 (9) 11 (9) 4 (4)
50–59 2101 (22) 264 (24) 235 (24) 38 (32) 29 (26)
60–69 3464 (36) 406 (37) 417 (42) 46 (39) 50 (44)
≥ 70 3248 (34) 345 (31) 238 (24) 23 (19) 30 (27)
Tumor location3 Pancreas head 7314 (83) 658 (82) 820 (90) 97 (92) 91 (88)
Pancreas body 622 (7) 58 (7) 31 (3) 5 (5) 4 (4)
Pancreas tail 845 (10) 86 (11) 63 (7) 3 (3) 8 (8)
Other 738 (8) 303 (27) 68 (7) 13 (11) 10 (9)
T stage4 T1 494 (5) 56 (5) 72 (7) 0 (0) 8 (8)
T2 1192 (13) 185 (17) 182 (19) 8 (7) 28 (26)
T3 7815 (82) 860 (78) 727 (74) 108 (93) 70 (66)
N stage5 N1 6339 (67) 805 (73) 703 (72) 97 (84) 60 (55)
Differentiation6 Well 858 (10) 149 (15) 91 (11) 12 (11) 3 (3)
Intermediate 4540 (52) 511 (52) 423 (51) 44 (40) 64 (63)
Poor/undifferentiated 3266 (38) 326 (33) 319 (38) 55 (50) 35 (34)
1Categorical data are shown as count (percentage [%]). For brevity, results for the counterparts in dichotomous variables are omitted. Records are complete
otherwise specified below
2The cancer incidence rates by sex in each country were retrieved from the Cancer Incidence in Five Continents Volume XI (CI5 XI) by the International Agency for
Research on Cancer (IARC), World Health Organization (WHO) which reports the incidence of cancers diagnosed from 2008 to 2012, standardized to the World
(WHO 2000–2025) Standard Population
3The percentages of pancreas head, body, tail, and overlapping cancers are the proportions compared to the total tumor cases of the four locations; “other”
includes overlapping lesion, pancreas duct, and not otherwise specified location, and its proportion is relative to the whole cases
4Missing T stage: the US: 18 (< 1%); Belgium: 4 (< 1%); the Netherlands: 1 (< 1%); Slovenia: 2 (2%); Norway: 7 (6%)
5Missing N stage: the US: 0 (0%); Belgium: 7 (1%); the Netherlands: 0 (0%); Slovenia: 2 (2%); Norway: 3 (3%)
6Missing differentiation: the US: 855 (9%); Belgium: 119 (11%); the Netherlands: 149 (15%); Slovenia: 7 (6%); Norway: 11 (10%)
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Prognostic nomogram
Construction
A nomogram incorporating prognostic factors remaining
after backward selection in the US (sex, age, T and N
stages, and differentiation) was established (Fig. 2a). The
nomogram illustrated age and differentiation to have the
largest contributions to prognosis. T and N stages
showed moderate impacts on survival. Each number/cat-
egory of these variables is assigned a score on the Points
scale. After summing up the total score and locating it
on the Total Points scale, a line drawn straight down to
the Median Survival or 1-/2-/3-/5-Year Survival Prob-
ability scale shows the estimated survival time or
probability at each time point. The model function is
provided in the Additional file 1: Supplementary Results.
Score assignment for specific categories of the variables
and survival for different accumulated scores are shown
in Table 5. The layout of an online version of the nomo-
gram is shown in Fig. 3.
An example of use
An example of how to use the nomogram is shown in
Fig. 2b. A 72-year-old woman with poorly differentiated,
T2N1M0 PaC who underwent resection and chemotherapy
would have 28 points for her age, 0 points for her sex, 53
points for T stage, 82 points for N stage, and 97 points for
Fig. 1 Kaplan-Meier overall survival curves for patients with resected stage I–II pancreatic cancer receiving chemotherapy in each country. The
95% confidence limits curves and the 95% Hall-Wellner bands are additionally shown. Median survival time (interquartile range) in months and 3-
year survival rates (95% confidence interval) are calculated and provided. IQR, interquartile range; CI, confidence interval
Table 2 Short- and long-term survival for resected pancreatic cancer patients receiving chemotherapy estimated by the Kaplan-
Meier method
Survival The US Belgium The Netherlands Slovenia Norway
OS (95% CI)1 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI)
Short-term survival
6-month 94 (94–95) 95 (94–96) 97 (96–98) 95 (89–98) 96 (91–99)
9-month 87 (86–87) 86 (84–88) 89 (87–91) 79 (70–85) 90 (83–94)
Long-term survival
1-year 77 (76–78) 77 (74–79) 79 (77–82) 69 (60–77) 77 (67–83)
2-year 47 (46–48) 46 (43–49) 44 (40–47) 39 (30–47) 46 (36–55)
3-year 31 (30–32) 29 (26–32) 29 (25–32) 21 (14–29) 27 (18–36)
5-year 19 (18–20) 17 (14–20) 20 (16–23) 10 (5–17) 21 (12–31)
1Results were calculated using the Kaplan-Meier method and are shown as survival proportions (95% confidence intervals) [%]
OS overall survival, CI confidence interval
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differentiation, totaling 260 points. The total points corres-
pond to the estimation of median survival time of < 20
months, a 1-year survival probability of 72%, a 2-year
survival probability of 38%, a 3-year survival probability
of 22%, and a 5-year survival probability of 12%, which
are consistent with the results generated by the online
tool (Fig. 3).
Calibration and validation
The nomogram was applied to the US and the European
countries for internal and external validations, respectively.
The calibration plots showed very good agreement between
nomogram-predicted and actual survival in the US, Belgium,
and the Netherlands (Fig. 4; plots were not shown in Slovenia
or Norway where the case number was too small to generate
meaningful calibration). Generally, the calibration was best for
2- and 3-year survival. In the training US cohort, the C-index
for the established nomogram was significantly higher than
that for the model based on both T and N stages (0.60, 95%
CI= 0.59–0.61 vs. 0.56, 95% CI= 0.56–0.57). In the validation
cohorts, C-indexes were also significantly higher for the
nomogram than for the Tand N stage-based model (Table 6).
Sensitivity analyses
Sensitivity analyses were performed for the derivative US
cohort (Table 6). Using positive lymph node number or
lymph node ratio instead of N stage in the nomogram
did not obviously change the C-index (by 0.00 and +
0.01, respectively). Replacing the sixth/seventh version of
both T and N stages with the eighth version also had
minimal impact on the C-index (by + 0.01). After includ-
ing examined lymph node number, tumor size, or both,
the C-index only changed by 0.0, + 0.01, and + 0.01, re-
spectively. Limiting the sample to patients diagnosed
after 2009 or white people did not change the C-index.
Within subgroups according to tumor location, C-index
was slightly higher than the overall one in body/tail
cancer (0.61).
Discussion
In our large population-based study, we identified vari-
ous factors independently associated with survival after
resection of PaC and for the first time established and
internationally validated a population-based nomogram
for predicting survival in resected PaC patients receiving
chemotherapy, which is robust, accurate, reliable, and
practical. However, like previous models [23, 24, 30–32],
our model had a modest C-statistic.
There are various reports on the prognostic factors for
patients who underwent resection for PaC [9–15]. A sys-
tematic review showed that with the exception of postsur-
gical blood transfusion, tumor characteristics (e.g., size,
Table 3 Association of demographic and clinical variables with overall survival for resected pancreatic cancer patients estimated by
adjusted multivariable Cox proportional hazards regression
Variable Category The US The US (white) Belgium The Netherlands Slovenia Norway
Used no. 8657 7170 979 833 109 96
HR (95% CI)1 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Year of diagnosis Per year; continuous 0.97 (0.96–0.98) 0.97 (0.96–0.98) 0.98 (0.95–1.01) 0.99 (0.95–1.03) 0.96 (0.89–1.03) 0.80 (0.69–0.93)
Age Per year; continuous 1.01 (1.01–1.01) 1.01 (1.01–1.01) 1.02 (1.01–1.02) 1.00 (0.99–1.01) 1.01 (0.99–1.04) 1.04 (1.00–1.08)
Sex Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Male 1.10 (1.05–1.16) 1.12 (1.06–1.18) 0.93 (0.80–1.07) 1.08 (0.91–1.29) 1.49 (0.96–2.32) 1.14 (0.67–1.95)
Tumor location Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pancreas body 1.03 (0.92–1.15) 1.04 (0.92–1.17) 1.34 (0.99–1.82) 1.19 (0.69–2.04) 1.33 (0.47–3.81) 0.40 (0.05–2.98)
Pancreas tail 1.02 (0.93–1.12) 1.03 (0.93–1.14) 1.00 (0.76–1.30) 0.85 (0.57–1.26) 0.39 (0.09–1.66) 2.67 (1.09–6.53)
Other2 1.02 (0.93–1.13) 1.03 (0.93–1.15) 0.95 (0.80–1.12) 0.92 (0.65–1.38) 0.83 (0.37–1.84) 0.89 (0.30–2.65)
T stage T1 0.66 (0.57–0.75) 0.70 (0.61–0.81) 0.68 (0.47–0.97) 0.48 (0.33–0.71) – 0.17 (0.04–0.72)
T2 0.86 (0.79–0.93) 0.88 (0.81–0.97) 0.89 (0.74–1.08) 1.02 (0.82–1.26) 0.70 (0.29–1.67) 0.89 (0.49–1.61)
T3 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
N stage N0 0.65 (0.61–0.69) 0.65 (0.61–0.69) 0.78 (0.66–0.92) 0.51 (0.41–0.64) 0.77 (0.40–1.51) 0.71 (0.39–1.29)
N1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Differentiation Well 0.60 (0.55–0.66) 0.59 (0.53–0.65) 0.68 (0.55–0.85) 0.48 (0.35–0.67) 0.57 (0.27–1.22) 0.31 (0.04–2.58)
Intermediate 0.77 (0.73–0.81) 0.78 (0.73–0.82) 0.81 (0.69–0.94) 0.61 (0.50–0.73) 0.82 (0.51–1.32) 0.93 (0.54–1.61)
Poor/undifferentiated 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
1HRs were calculated by Cox proportional hazard regression with adjustment for year of diagnosis, age, sex, tumor location, T, N, and M stages, histology, and
differentiation. In stratified analyses, the stratification factor was omitted from the model. Statistically significant HRs are shown in italics
2Other: pancreas duct, overlapping lesion, and not otherwise specified location
HR hazard ratio, CI confidence interval, −, not available
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Table 4 Association of survival with potential prognostic factors available in at least one registry for resected pancreatic cancer
estimated by adjusted Cox proportional hazard regression
Variable The US Belgium The Netherlands Slovenia
n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI)
Resection margin
Negative – – – – 637 1.00 (reference) 51 1.00 (reference)
Positive – – – – 291 1.36 (1.12–1.65) 34 1.54 (0.82–2.88)
Hospital type
Non-academic – – 497 1.00 (reference) 510 1.00 (reference) – –
Academic – – 608 0.89 (0.77–1.03) 472 0.79 (0.66–0.94) – –
Tumor size
≤ 2 cm 1490 1.00 (reference) – – – – – –
2–3 cm 3146 1.23 (1.12–1.35) – – – – – –
3–4 cm 2487 1.38 (1.25–1.52) – – – – – –
4–5 cm 1229 1.60 (1.44–1.78) – – – – – –
> 5 cm 938 1.56 (1.39–1.75) – – – – – –
T stage (8th version)
T1 1490 0.62 (0.57–0.68) – – – – – –
T2 5633 0.81 (0.76–0.87) – – – – – –
T3 2167 1.00 (reference) – – – – – –
Positive LN number (continuous) 9426 1.05 (1.04–1.06) – – 974 1.07 (1.04–1.10) – –
N stage (8th version)
N0 (0 positive LNs) 3180 1.00 (reference) – – 280 1.00 (reference) – –
N1 (1–3 positive LNs) 3885 1.42 (1.33–1.51) – – 416 1.68 (1.33–2.13) – –
N2 (≥ 4 positive LNs) 2244 1.84 (1.72–1.98) – – 278 2.43 (1.89–3.12) – –
Harvested LN number (continuous) 9484 0.99 (0.99–0.99) – – 959 0.99 (0.98–1.00) – –
LN ratio (continuous) 9138 2.60 (2.26–3.00) – – 945 3.15 (2.05–4.84) – –
ECOG score
0 – – 140 1.00 (reference) – – – –
1 – – 662 0.96 (0.76–1.20) – – – –
≥ 2 – – 63 1.04 (0.73–1.47) – – – –
Resection type
Pancreatoduodenectomy 7108 1.00 (reference) – – 877 1.00 (reference) – –
Distal pancreatectomy 1142 1.02 (0.92–1.14) – – 88 1.33 (0.61–2.91) – –
Total pancreatectomy 1102 1.07 (0.99–1.15) – – 10 0.98 (0.36–2.65) – –
Comorbidity
Cardiovascular disease (yes v no) – – – – 30/119 1.33 (0.69–2.57) – –
Hypertension (yes v no) – – – – 39/110 1.01 (0.59–1.75) – –
Diabetes (yes v no) – – – – 33/116 1.34 (0.76–2.38) – –
Pulmonary disease (yes v no) – – – – 14/135 1.96 (0.88–4.36) – –
Number of comorbidities
0 – – – – 52 1.00 (reference) – –
1 – – – – 48 1.48 (0.84–2.62) – –
≥ 2 – – – – 49 1.86 (1.00–3.46) – –
1The main Cox proportional hazard regression models adjusted for year of diagnosis, age, sex, tumor location, T, N, and M stages, histology, and differentiation.
HRs were calculated after N stage was replaced by metastatic node number (group) or lymph node ratio, or after the other investigated variables were included
one by one into the main models. Statistically significant HRs are shown in italics
HR, hazard ratio; CI, confidence interval; LN, lymph node; ECOG, Eastern Cooperative Oncology Group; −, not available
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lymph node status, and differentiation) were the only fea-
tures significantly associated with survival after pancreatic
resection [9]. Particularly, PaC size > 2 cm was an inde-
pendent factor associated with poor post-surgical progno-
sis [10], and this category has been incorporated in both
the sixth/seventh and the eighth TNM staging systems
[33, 34]. Notably, neural invasion was also determined to
be an independent prognostic factor in PaC [11]. Through
multivariable analyses, we demonstrated that older age,
more advanced T and N stages, and poorer differentiation
were independently associated with lower overall survival
in resected PaC across most countries. In registries with
available information, resection margin, hospital type,
tumor size, metastatic and harvested lymph node num-
bers, lymph node ratio, and comorbidity number were
also associated with prognosis. These findings are mostly
consistent with previous literature [9–15, 35, 36] and add
insights into the association strengths for resected PaC
patients receiving chemotherapy at the population level
and into the comparisons between countries. Some pa-
tient (e.g., age and comorbidities) and clinical characteris-
tics (e.g., hospital type) were further identified to be
prognostically significant. While previous studies have
drawn differing conclusions regarding the association
between resection type and survival [35, 36], our
population-based investigation of chemotherapy-treated
resected PaC patients did not show a significant associ-
ation. Furthermore, we found mostly no significant associ-
ations between tumor location and survival.
Notably, overall, the contribution of T or N stage to
postoperative survival was mostly not greater than that
of differentiation. Categorization of tumor size and
Fig. 2 Prognostic nomogram for patients with resected stage I–II pancreatic cancer receiving chemotherapy derived from the US cohort (a) and
an example on how to use the nomogram (b). Each number/category of the prognostic variables is assigned a score on the Points scale. After
summing up the total score and locating it on the Total Points scale, a line drawn straight down to the Median Survival or 1-/2-/3-/5-Year Survival
scale shows the median survival time and estimated survival probability at each time point. Age is in years
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Table 5 Score assignment for specific categories of the
variables included in the nomogram
Prognostic factors
Variable Category Score
Sex Female 0
Male 18
Age (years) 25 42
30 34
35 27
40 19
45 11
50 4
55 0
60 5
65 18
70 24
75 33
80 46
85 59
90 73
95 86
100 100
T stage T1 0
T2 53
T3 78
N stage N0 0
N1 82
Differentiation Well 0
Intermediate 47
Poor/undifferentiated 97
Median survival
Total score Median survival (months)
251 20
152 30
99 40
64 50
43 60
27 70
13 80
0 90
1-year survival
Total score 1-year survival probability
345 0.60
313 0.65
277 0.70
236 0.75
Table 5 Score assignment for specific categories of the
variables included in the nomogram (Continued)
187 0.80
126 0.85
44 0.90
2-year survival
Total score 2-year survival probability
358 0.20
329 0.25
302 0.30
276 0.35
250 0.40
224 0.45
197 0.50
169 0.55
138 0.60
106 0.65
70 0.70
29 0.75
3-year survival
Total score 3-year survival probability
342 0.10
305 0.15
273 0.20
245 0.25
218 0.30
192 0.35
166 0.40
139 0.45
112 0.50
84 0.55
54 0.60
21 0.65
5-year survival
Total score 5-year survival probability
323 0.05
272 0.10
235 0.15
204 0.20
175 0.25
148 0.30
122 0.35
96 0.40
70 0.45
43 0.50
15 0.55
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Fig. 3 Layout of an online version of the developed nomogram with Evidencio (https://www.evidencio.com/models/show/1258)
Fig. 4 Calibration curves for 1-, 2-, 3-, and 5-year overall survival prediction in the primary training (the US) and validation cohorts (Belgium, the
Netherlands, Slovenia, and Norway). Nomogram-predicted survival is plotted on the x axis and actual survival on the y axis. The vertical bars at
the top represent the frequency of the predicted probability of survival. A plot along the 45-degree line indicates a perfect calibration model
where the predicted probabilities are identical to the actual proportions
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number of metastatic lymph nodes following the eighth
TNM staging system [33, 34] discriminated survival well,
supporting the implementation of the new system. Not-
ably, harvested lymph node number was positively asso-
ciated with survival. The relevance of harvested lymph
node number for survival has remained controversial in
PaC [37, 38]. Possible reasons supporting the positive as-
sociation include that more metastasized lymph nodes
may be removed with more extensive sampling, which
also results in more precise staging, guiding appropriate
post-surgical treatment.
Estimating mortality risk might impact treatment plan-
ning and provide information helpful for patient stratifica-
tion in study design, contributing to better equivalence
between study arms [39]. Post-surgical survival for
patients with PaC is remarkably heterogeneous, even with
the same TNM stage [14, 40, 41]. To our knowledge, the
nomogram we developed is the first one derived from a
large population-based database with long-term follow-up
for predicting overall survival in patients with resected
stage I–II PaC receiving chemotherapy, with international
validations in multiple European national datasets. There
is a previous institutional nomogram [23] developed by
Memorial Sloan-Kettering Cancer Center (MSKCC) in
2004 for predicting post-surgical survival in Western PaC
patients not accounting for chemotherapy, with three ex-
ternal institutional validation attempts [30–32]. Based on
institutional patient cohorts diagnosed many years ago
[23, 30–32], the score assignment of several variables
might not be optimal currently using the MSKCC
Table 6 Concordance indexes for resected pancreatic cancer in training and validation cohorts and in sensitivity analyses for the
training US cohort
Model modification/subgroup Concordance index 95% confidence interval
Training cohort
The US, our nomogram 0.60 0.59–0.61
The US, model based on both T and N stages 0.56 0.56–0.57
Validation cohorts
Belgium, our nomogram 0.58 0.55–0.60
Belgium, model based on both T and N stages 0.54 0.52–0.56
The Netherlands, our nomogram 0.62 0.59–0.65
The Netherlands, model based on both T and N stages 0.56 0.54–0.59
Slovenia, our nomogram 0.58 0.51–0.65
Slovenia, model based on both T and N stages 0.52 0.47–0.57
Norway, our nomogram 0.63 0.55–0.71
Norway, model based on both T and N stages 0.61 0.54–0.68
Sensitivity analyses for the training US cohort
Replacement
Age group in place of continuous age 0.59 0.59–0.60
Metastatic lymph node number in place of N stage 0.60 0.59–0.61
Lymph node ratio in place of N stage 0.61 0.61–0.62
The 8th version of T stage in place of the original stage 0.61 0.60–0.61
The 8th version of N stage in place of the original stage 0.60 0.59–0.61
The 8th version of T & N stages in place of the original stages 0.61 0.60–0.62
Addition
Harvested lymph node added 0.60 0.60–0.61
Tumor size added 0.61 0.60–0.61
Harvested lymph node & tumor size added 0.61 0.60–0.62
Subgroup
Diagnosis after 2009 0.60 0.59–0.61
White ethnicity 0.60 0.59–0.61
Pancreas head 0.60 0.59–0.61
Pancreas body & tail 0.61 0.59–0.63
Concordance indexes in sensitivity analyses greater than that for the overall nomogram in the US are highlighted in italics
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nomogram, which might also be limited in
generalizability. The MSKCC nomogram did not employ a
backward selection process and incorporated some de-
tailed surgical (e.g., portal vein resection and splenectomy)
and symptom parameters (back pain and weight loss).
Notably, portal vein resection and splenectomy might not
be routine procedures during pancreatectomy, and report-
ing of symptoms might show great interpersonal varia-
tions. Our population-based nomogram thus represents a
more updated prognostic model compared to the MSKCC
nomogram (Additional file 1: Table S5). The wide geo-
graphical distribution of patients and large sample size
further enhanced the international representativeness and
generalizability of our nomogram.
Resection margin, which reflects the radicality of sur-
gery, has not received a universal standard definition in
PaC [42, 43], and its relevance for survival remains
highly controversial [44, 45]. While we showed a positive
association of survival with negative margin in the
Netherlands, the strength was not greater than that of
the association with T stage, N stage, or differentiation.
We did not incorporate this variable in our nomogram
for better generalizability. It is encouraged to incorpor-
ate margin status into our nomogram when a standard
definition comes.
Calibration plots demonstrated very good agreement
between nomogram-predicted and actual survival, which
assures the repeatability and reliability of our nomo-
gram. Importantly, the model based on the US dataset
also fits the multiple European national cohorts, which
supports the potential for the generalization and inter-
national utilization of our nomogram, irrespective of the
potential health care disparity across countries. Discrim-
ination of the nomogram, as highlighted by the C-index,
was significantly and markedly higher compared to the
model based on T and N stages only. In the external val-
idation cohorts, the discriminative potency only slightly
changed. Our model performed similarly well across
countries, potentially facilitating patient allocation in
international studies.
In sensitivity analyses, we examined various alternative
models by for instance incorporating positive lymph
node number or lymph node ratio as a continuous vari-
able in place of N stage into the nomogram, and the dis-
crimination ability basically remained the same,
supporting the robustness of our model.
Notably, the eighth edition of TNM staging system has
been implemented since 2018 [33, 34]. Compared to the
sixth/seventh version, in the eighth version new categor-
ies of tumor size (≤ 2, 2–4, and > 4 vs. ≤ 2 and > 2 cm)
and positive node number (0, 1–3, and ≥ 4 vs. 0 and ≥ 1)
are incorporated into T and N staging, respectively [26,
33, 34]. However, after integrating these factors either as
continuous or corresponding categorical variables into
our nomogram, the performance did not markedly
change. After transforming the SEER-18 staging data ac-
cording to the eighth edition following Kamarajah et al.
[26], the performance also remained very similar. More-
over, it will take considerable follow-up time for the sur-
vival associated with the new staging system to be
adequately assessed. Therefore, our nomogram will still
be applicable without compromised accuracy in the
coming years.
Strengths of our study include the international
population-based design, the largest number of patients
with resected PaC ever investigated, the extensive poten-
tial prognostic factors studied, the uniformly and consist-
ently defined variables especially TNM stage across
countries, and the consistency and quality control in
reporting through applying rigorous registry data stan-
dards. Analyses were performed separately in each re-
spective country without pooling, which avoids the
impact of the potential heterogeneity across countries.
Our work may have important clinical impacts and
provides to our knowledge the first population-based
model which can predict survival for patients with stage
I–II PaC who underwent resection and chemotherapy.
The model is robust, accurate, well-generalizable, prac-
tical, and easy-to-use. Our model may offer personalized
patient survival estimates and facilitate clinical counsel-
ing for both patients and doctors. Having an idea about
the estimated survival of a specific patient could influ-
ence plans on follow-up and surveillance (e.g., frequency
and examination modality) and thus possibly guide re-
source allocation. For some proportion of the resected
patients considering further treatment, the predicted
survival might encourage receipt of further chemother-
apy. The international validation assures that our model
could be used for survival stratification in international
studies.
Patients with resected PaC do not respond equally to
chemotherapy, and accordingly, the calibration plots also
suggest that individual survival varied greatly despite the
relatively consistent comprehensive survival across
countries. Our study will help to initially stratify this
patient population into subgroups with discrepant sur-
vival, and might serve as a platform for developing fur-
ther endeavors to understand factors associated with
chemotherapy responses and survival in resected PaC,
including precise, individualized, and personalized gen-
omic and proteomic survivorship investigations.
Like any observational registry-based investigation, our
study also has some limitations. Our model predicts sur-
vival at the average population level, and when applying
this model in specific centers or regions with different
care patterns, there could be some inconsistencies
between predicted and actual survival. Nevertheless, as
revealed by the calibration plots, the real-world survival
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was still in good accordance with the prediction for a
single individual. Residual confounding is a concern.
Some significant variables (e.g., tumor size) were only
registered in certain databases. Differences in survival
pattern across countries might be partly associated with
variation in the prescription of chemotherapy and/or the
underlying ethnic/racial distribution, even though asso-
ciation results remained similar after limiting the US
cohort to white. Notably, there were some differences in
patient and tumor characteristics across registries. For
instance, in Slovenia, tumors were generally more ad-
vanced and poorly differentiated, and the actual survival
was the lowest. Nevertheless, these variables were
adjusted for in our multivariable analyses.
Population-based registries collected limited information
on variables including family and patient health history and
individual-level socioeconomic status. In addition, we were
unable to determine the molecular or genetic subtype of
PaC [16], which probably plays a role in prognosis and
explains the moderate C-index of our nomogram. Accord-
ingly, our nomogram is limited by failure to incorporate
these and other recognized prognostic parameters (e.g.,
neurovascular invasion and type of chemotherapy). Further
efforts on collection and incorporation of more relevant
variables are encouraged to improve this model.
Notably, all known models predicting PaC survival per-
form very modestly [23, 24, 30–32]. Our nomogram with
selection of only chemotherapy-treated resected PaC pa-
tients does not perform better compared to previous
models with selection of all patients undergoing resection
[23, 24, 30–32], which might limit the added value of the
selection for the current nomogram. The lack of detailed
information on chemotherapy which has not been routinely
collected in most registries is another limitation of this
population-based registry-based study. Collection of such
information is strongly encouraged in future registration
practice. During the study period, the type of chemotherapy
was mainly gemcitabine monotherapy, followed by
5-fluorouracil-based therapy. The ESPAC-3 [46] and RTOG
97-04 randomized trials [47] demonstrated similar efficacy
and effectiveness regarding survival between gemcitabine
and 5-fluorouracil in the adjuvant setting. The landscape of
systemic treatment (e.g., agent and formula) and treatment
sequence for PaC are rapidly changing, which might limit
the possible use of this nomogram.
Despite the moderate C-index, the agreement between
predicted and actual survival was very good. All variables
included in our nomogram are easily available in clinics,
compared to the not routinely measured and costly mo-
lecular markers. It is herein the first time that the contri-
butions of these risk factors are quantified and
integrated into a single model for survival prediction in
resected and chemotherapy-treated PaC with inter-
national validations.
Conclusions
This large international population-based investigation re-
vealed independent factors associated and not associated
with survival in patients with resected stage I–II PaC re-
ceiving chemotherapy, with country-specific association
patterns and strengths. We further established and inter-
nationally validated a novel, robust, and reliable
survival-predicting model, which may provide the basis for
more precise individualized survival estimation and which
could be useful for clinical counseling. Our nomogram in
line with all known models predicting survival in resected
PaC performs modestly.
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